Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms × Nivolumab × Clear all

Phase

Phase 1 28 Phase 1/2 24 Phase 2 19 Phase 3 3 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 6 Stomach Neoplasms 3 Adenocarcinoma Of Esophagus 3 Carcinoma, Hepatocellular 2 Uveal Melanoma 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Hepatitis B 1 Gliosarcoma 1 GATA2 Deficiency 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Advanced or Metastatic Solid Malignancies 1 Adenocarcinoma of Lung 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 3 Standard of Care 3 Oxaliplatin 3 Melatonin 3 Gemcitabine 3 Fluorouracil 3 Drug Therapy 3 Capecitabine 3 gamma-Globulins 2 cobimetinib 2 Water 2 Vemurafenib 2 Sirolimus 2 Saline Solution 2 Methylphenidate 2 Lidocaine 2 Leucovorin 2 Immunoglobulins, Intravenous 2 Docetaxel 2 Ciprofloxacin 2 valrubicin 1 trametinib 1 sotrovimab 1 sintilimab 1 relatlimab 1 racemetyrosine 1 pertuzumab 1 pembrolizumab 1 osimertinib 1 netupitant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03470922 2025-09-09

RELATIVITY-047

Bristol-Myers Squibb

Phase 2/3 Active not recruiting

714 enrolled 17 charts 1 FDA

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡